The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer.

Autor: Tong Z; Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.; NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, P. R. China.; Department of Urology, Klinikum rechts der Isar, Technical university of Munich, Munich, Germany.; Department of Urology, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China., Zhao Y; Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.; NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, P. R. China., Bai S; NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, P. R. China.; Department of Urology, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China., Ebner B; Department of Urology, Klinikum rechts der Isar, Technical university of Munich, Munich, Germany.; Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany., Lienhard L; Department of Urology, Klinikum rechts der Isar, Technical university of Munich, Munich, Germany., Zhao Y; Department of Urology, Klinikum rechts der Isar, Technical university of Munich, Munich, Germany., Wang Z; Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.; NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, P. R. China., Pan Q; Department of Urology, Klinikum rechts der Isar, Technical university of Munich, Munich, Germany.; Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China., Guo P; Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.; NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, P. R. China., Bracht T; Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany.; Clinic for Anesthesiology, Intensive Care and Pain Therapy, University Medical Center Knappschaftskrankenhaus Bochum, Bochum, Germany., Sitek B; Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany.; Clinic for Anesthesiology, Intensive Care and Pain Therapy, University Medical Center Knappschaftskrankenhaus Bochum, Bochum, Germany., Gschwend JE; Department of Urology, Klinikum rechts der Isar, Technical university of Munich, Munich, Germany., Xu W; Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.; NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, P. R. China., Nawroth R; Department of Urology, Klinikum rechts der Isar, Technical university of Munich, Munich, Germany.
Jazyk: angličtina
Zdroj: Cancer communications (London, England) [Cancer Commun (Lond)] 2024 Jun; Vol. 44 (6), pp. 700-704. Date of Electronic Publication: 2024 Mar 11.
DOI: 10.1002/cac2.12532
Databáze: MEDLINE